Clinical Trial Update: N-DOSE: A Dose Optimization Trial of Nicotinamide Riboside in Parkinson's Disease [Phase 2]

View source ↗

Summary

A Phase 2 trial assessing dose optimization of nicotinamide riboside in Parkinson disease has completed.

Upgrade for the full analysis, importance score, and drug timeline.

Diseases / indications

• Parkinson Disease

Drugs mentioned

• Nicotinamide Riboside (nicotinamide riboside)

Snippet

Sponsor: Haukeland University Hospital | Conditions: Parkinson Disease | Phase 2 | Status: COMPLETED